Technical Analysis for ADVM - Adverum Biotechnologies, Inc.

Grade Last Price % Change Price Change
grade C 14.17 1.43% 0.20
ADVM closed up 1.43 percent on Monday, July 22, 2019, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Earnings due: Aug 7

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical ADVM trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
MACD Bearish Signal Line Cross Bearish 1.43%
1,2,3 Pullback Bullish Bullish Swing Setup 1.43%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.43%
Calm After Storm Range Contraction 1.43%
Inside Day Range Contraction 1.43%
Wide Bands Range Expansion 1.43%

Older signals for ADVM ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Disease Gene Therapy Macular Degeneration Wet Age Related Macular Degeneration Gene Therapy Products Adverum Biotechnologies Gene Therapy Of The Human Retina Rare Genetic Disease Retinoschisis
Is ADVM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 16.3834
52 Week Low 2.62
Average Volume 1,083,324
200-Day Moving Average 6.1182
50-Day Moving Average 11.2402
20-Day Moving Average 13.342
10-Day Moving Average 14.945
Average True Range 0.9444
ADX 41.57
+DI 29.912
-DI 24.4738
Chandelier Exit (Long, 3 ATRs ) 13.5502
Chandelier Exit (Short, 3 ATRs ) 13.5432
Upper Bollinger Band 17.0586
Lower Bollinger Band 9.6254
Percent B (%b) 0.61
BandWidth 55.712787
MACD Line 1.0733
MACD Signal Line 1.1871
MACD Histogram -0.1137
Fundamentals Value
Market Cap 613.38 Million
Num Shares 43.3 Million
EPS -1.52
Price-to-Earnings (P/E) Ratio -9.32
Price-to-Sales 75.42
Price-to-Book 0.71
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.88
Resistance 3 (R3) 14.86 14.61 14.76
Resistance 2 (R2) 14.61 14.43 14.62 14.72
Resistance 1 (R1) 14.39 14.32 14.50 14.41 14.68
Pivot Point 14.14 14.14 14.20 14.15 14.14
Support 1 (S1) 13.92 13.96 14.03 13.94 13.66
Support 2 (S2) 13.67 13.85 13.68 13.62
Support 3 (S3) 13.45 13.67 13.58
Support 4 (S4) 13.47